Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$205.95 - $280.43 $12 Million - $16.4 Million
-58,357 Reduced 39.55%
89,207 $24.8 Million
Q3 2022

Nov 08, 2022

BUY
$203.3 - $244.17 $8.37 Million - $10.1 Million
41,185 Added 38.72%
147,564 $30.9 Million
Q2 2022

Aug 15, 2022

SELL
$174.81 - $241.14 $16.2 Million - $22.4 Million
-92,804 Reduced 46.59%
106,379 $25.1 Million
Q1 2022

May 16, 2022

BUY
$166.16 - $213.96 $11.5 Million - $14.9 Million
69,429 Added 53.51%
199,183 $35.7 Million
Q4 2021

Feb 14, 2022

SELL
$184.32 - $216.08 $17 Million - $20 Million
-92,340 Reduced 41.58%
129,754 $28 Million
Q3 2021

Nov 15, 2021

BUY
$179.86 - $214.88 $1.08 Million - $1.29 Million
6,009 Added 2.78%
222,094 $41 Million
Q2 2021

Aug 16, 2021

BUY
$170.47 - $211.93 $175,754 - $218,499
1,031 Added 0.48%
216,085 $38.8 Million
Q1 2021

May 14, 2021

SELL
$153.94 - $174.85 $20.5 Million - $23.2 Million
-132,847 Reduced 38.19%
215,054 $36 Million
Q4 2020

Feb 16, 2021

BUY
$101.87 - $151.79 $2.74 Million - $4.09 Million
26,942 Added 8.39%
347,901 $52.8 Million
Q3 2020

Nov 13, 2020

BUY
$99.9 - $121.13 $1.64 Million - $1.99 Million
16,397 Added 5.38%
320,959 $32.4 Million
Q2 2020

Aug 13, 2020

BUY
$92.74 - $125.82 $6.58 Million - $8.93 Million
71,003 Added 30.4%
304,562 $36.9 Million
Q1 2020

May 13, 2020

BUY
$79.39 - $115.35 $3.57 Million - $5.18 Million
44,914 Added 23.81%
233,559 $22.1 Million
Q4 2019

Feb 14, 2020

SELL
$78.31 - $95.34 $420,446 - $511,880
-5,369 Reduced 2.77%
188,645 $16.6 Million
Q3 2019

Nov 14, 2019

BUY
$74.85 - $85.99 $14.5 Million - $16.7 Million
194,014 New
194,014 $15.5 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Sofinnova Investments, Inc. Portfolio

Follow Sofinnova Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.